Septic ShockPhase 2HALONCT03378466
Heparin Anticoagulation in Septic Shock
A Phase 2 study testing Unfractionated heparin and Venous thromboprophylaxis (VTE) in people with Septic Shock and Vasodilatory Shock, run by University of Manitoba at 51 sites in 7 countries.
Trial summary
This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Septic Shock, Vasodilatory Shock
- What is being tested?
- Unfractionated heparin and Venous thromboprophylaxis (VTE)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 178 participants
- Where
- 51 sitesin 7 countries
- Study dates
- 12 Mar 2018to 31 Dec 2021
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥ 18 years of age
- Refractory hypotension documented within 18 hours prior to enrolment that requires the institution and ongoing use of vasopressor agents, (phenylephrine, norepinephrine, vasopressin, epinephrine, midodrine or dopamine >5 mcg/kg/min) at the time of enrolment. Refractory hypotension is defined as a systolic blood pressure (SBP) less than 90 mm Hg, or a systolic blood pressure more than 30 mm Hg below baseline, or a mean arterial pressure (MAP) less than 65 mm Hg and receipt of ≥ 2 litres of intravenous fluid for the treatment of hypotension (≥ 1 litre if dialysis dependent end-stage renal disease or if the patient is felt to be in congestive heart failure).
- At least 1 other new organ dysfunction (in addition to refractory hypotension), defined by the following:
- Creatinine ≥1.5x the known baseline creatinine, or ≥ 26.5 µmol/L increase or <0.5 mL/kg of urine output for 6-12 hours according to the KDIGO [Kidney Disease improving Global Outcomes (KDiGO)] guideline definition of acute kidney injury.
- Need for invasive mechanical ventilation or a P/F ratio <250
- Platelets <100 x109/L, or a drop of 50 x109/L in the 3 days prior to enrolment
- Arterial pH < 7.30 or base deficit > 5 mmol/L in association with a lactate > 4.0 mmol/L
Who cannot join
- Other forms of shock including cardiogenic, hemorrhagic, hypovolemic, neurogenic, or obstructive shock.
- Clinical suspicion or confirmation of a viral hemorrhagic shock syndrome including, but not limited to, dengue fever
- Rapid clinical improvement; vasopressors likely to be discontinued in the next 6 hours
- Received vasopressor therapy for greater than 18 hours prior to enrolment
- Bleeding Risk:
- Clinical: Active bleeding; head trauma; intracranial surgery or stroke within 3 months; history of intracerebral arteriovenous malformation, cerebral aneurysm or mass lesions of the central nervous system; history of a bleeding diatheses; gastrointestinal bleeding within 6 weeks; presence of an epidural or spinal catheter; selected cases of recent surgery where IV therapeutic UFH is considered contraindicated
Show all 13Show fewer
- Laboratory: Platelet count <50 x109/L, INR >2.0, or baseline aPTT >50 seconds prior to enrolment
- Known or suspected adverse reaction to UFH including heparin induced thrombocytopenia (HIT).
- Use of any of the following treatments: UFH to treat a thrombotic event within 12 hours before enrolment; LMWH at a higher dose than recommended for prophylactic use within 12 hours before the infusion; warfarin (if used within 7 days before study entry AND if the INR exceeds 2.0 at enrolment); thrombolytic therapy within 3 previous days; use of IIb/IIIa inhibitors within the previous 7 days.
- Need for therapeutic anticoagulation
- Terminal illness with a life expectancy of less than 3 months, or no commitment to aggressive care.
- Consent declined from patient or authorized 3rd party
- Physician refusal
Trial locations and contacts
51 sites in 7 countries.
51 sites in 7 countries
Brazil29 sites
Hospital Sao Jose
Altamira
Hospital Novo Atibaia
Atibaia
Hospital de Amor (Barretos)
Barretos
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte
Hospital Tacchini
Bento Gonçalves
Hospital de Brasília
Brasília
Hospital Ortopedico e Medicina Especializada ltda. - HOME
Brasília
Instituto de Cardiologia do Distrito Federal
Brasília
Hospital Maternidade São José
Colatina
Hospital Baía Sul
Florianópolis
Hospital Nereu Ramos
Florianópolis
Hospital de Amor Jales
Jales
Unimed Cariri Hospital
Juazeiro do Norte
Hospital de Clínicas de Porto Alegre
Porto Alegre
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
Ribeirão Preto
Hospital Bruno Born
Rio Grande
Hospital da Cidade
Salvador
Santa Casa de São João Del Rei
São João del Rei
Hospital AC Camargo
São Paulo
Hospital Beneficência Portuguesa
São Paulo
Hospital da Luz
São Paulo
Hospital das Clinicas da faculdade de Medicina de Universidade de São Paulo
São Paulo
Hospital e Maternidade Sao Vicente
São Paulo
Hospital Santa Paula
São Paulo
Hospital Sepaco
São Paulo
Instituto de Assistência Médica ao Servidor Público Estadual de São Paulo
São Paulo
Universidade Federal de Sao Paulo - UNIFESP
São Paulo
Hospital Ana Nery
Taguatinga
Canada11 sites
Foothills Medical Centre
Calgary, Alberta, T2N 2T9
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6
The Ottawa Hospital - Civic Campus
Ottawa, Ontario, K1Y 4E9
Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval
Québec, Quebec, G1V 4G5
Hopital de l'Enfant-Jesus
Québec, G1J 1Z4
Niagara Health System - St Catharines Site
Saint Catherines, Ontario, L2S 0A9
St Michael's Hospital
Toronto, Ontario, M5B 1W8
Vancouver Island Health Authority
Victoria, British Columbia, V8R 1J8
St Boniface General Hospital
Winnipeg, Manitoba, R2H 2A6
Health Sciences Centre Winnipeg
Winnipeg, Manitoba, R3A 1R9
Pakistan4 sites
Dr Ruth K.M. PFAU Civil Hospital
Karachi
Shaheed Mohtarma Benazir Bhutto Trauma Center
Karachi
The Indus Hospital
Karachi
Mayo Hospital Lahore
Lahore
Philippines3 sites
The Asian Hospital
Manila
The Medical City
Manila
The Philippines General Hospital
Manila
Greece2 sites
ATTIKON University Hospital
Athens
Korgialeneion Benakeion Hospital
Athens
About this study
Official title: Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT
This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
Read the detailed description
Background and significance: Sepsis and septic shock account for 10% of admissions to the intensive care unit and constitute the second most frequent cause of death among admitted patients. The mortality rate associated with septic shock ranges from 30% to 50% and death is often due to multiple organ dysfunction coupled with systemic inflammation. Given the pathobiological relationship between coagulation and inflammation in sepsis, treatment with anticoagulants has been investigated in this population. Multiple lines of evidence suggest that heparin, a widely available, inexpensive anticoagulant, may improve clinical outcomes in sepsis, but high quality evidence to guide practice is lacking.
Hypothesis: Intravenous (IV) unfractionated heparin (UFH) reduces mortality and morbidity when administered to patients with suspected septic shock.
Study Design: A pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
Setting: To increase the external validity/generalizability of the trial results, 20 sites in 4 countries will participate.
Study Population: Patients with systemic inflammation, vasopressor dependent shock, and signs of organ dysfunction.
Interventions: IV infusion of UFH at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to usual care to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x that of the reference aPTT value (approximately 59-99 seconds). Alternately, therapeutic anti-Xa values (ie. values typically targeted for the treatment of venous thromboembolism) can be targeted based on local practice. Duration of heparin infusion is for a maximum of 5 days (120 hours) or until death, ICU discharge or discontinuation of vasopressors. The dose of UFH has been informed by our observational study and meta-analysis that showed a benefit of UFH in patients receiving therapeutic doses.
Control group: Local standard care for venous thromboprophylaxis (i.e. not therapeutic) which may include SC LMWH, SC UFH, sequential compression devices or graduated compression stockings.
Outcomes: At the end of the HALO international phase II trial, an international DSMB will be presented with by-group efficacy (vasopressor-free days) data in the context of 90-day mortality, and safety (bleeding and transfusion). With these data the DSMB will suggest: a) terminating enrollment for futility (lack of efficacy) or harm, or b) continuing to the phase III trial along with a recommended sample size to detect a clinically relevant difference in 90-day mortality. Patients will be analyzed according to the treatment group to which they are allocated. By-group data will remain blinded to study investigators so that these patients may be included in the HALO international phase III RCT. Our analytic approach provides a rationale to either stop, or to justify further investment in a large international phase III trial.
- Conditions
- Septic Shock, Vasodilatory Shock
- Being tested
- Unfractionated heparin, Venous thromboprophylaxis (VTE)
- Medical subject headings
- Shock, Septic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Unfractionated heparinDrug
Also called Heparin
UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
Venous thromboprophylaxis (VTE)Other
May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
| Study group | Role | What they receive |
|---|---|---|
| Unfractionated Heparin (UFH) | Experimental | UFH initiated at 18 IU/kg/hr Receives: Drug: Unfractionated heparin |
| Venous thromboprophylaxis (VTE) | Other | as per local standard Receives: Other: Venous thromboprophylaxis (VTE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vasopressor-free days.
The goal of phase II trial is to provide the international Data Safety Monitoring Committee (DSMC) with a sensible estimate to justify continued enrollment in an adaptive (sample size) trial. Vasopressor use, reflecting cardiovascular collapse due to overwhelming systematic inflammation, is a key inclusion criterion for the trial and durable discontinuation of such drugs and meaningful clinical improvement. Vasopressor-free days has been recommended as a preferred clinical outcome in phase II trials in critical illness.
Measured: 30 days
Secondary outcomes (11)
Clinical Outcome #1 - ICU mortality
Survival
Measured: From date of randomization until the first documentation of death from any cause or ICU discharge date or 90 days, whichever came first
Clinical Outcome #2 - Hospital mortality
Survival
Measured: From date of randomization to the first documentation of death from any cause or hospital discharge date or 90 days, whichever came first.
Clinical Outcome #3 - 90-day mortality
Survival
Measured: Up to day 90
Clinical Outcome # 4 - ∆SOFA score (Sequential Organ Failure Assessment)
Organ failure assessment using the SOFA scoring tool
Measured: Daily from randomization to ICU discharge or hospital discharge or time of death or to study day 9 if still in ICU or hospital.
Clinical Outcome # 5 - Hospital-free days to day 90
Hospital admission duration in the context of survival
Measured: from hospital admission to hospital discharge or time of death to day 90
Clinical Outcome #6 - Renal replacement therapy-free days to day 28
Renal replacement therapy duration in the context of survival
Measured: from start of renal replacement therapy to study day 28
Safety Outcome #1 - Major Bleeding
Rates of major bleeding using a validated bleeding assessment tool
Measured: Assessed daily to day 8
Safety Outcome #2 - Minor Bleeding
Rates of minor bleeding using a validated bleeding assessment tool
Measured: Assessed daily to day 8
Safety Outcome #3 - Suspected HIT (Heparin induced thrombocytopenia)
Incidence of any laboratory testing for HIT including screening or confirmatory tests
Measured: Assessed daily to day 8
Safety Outcome #4 - Confirmed HIT (Heparin induced thrombocytopenia)
Postive confirmatory HIT test (one of Serotonin release assay (SRA) or Heparin induced platelet aggregation (HIPA))
Measured: Assessed daily to day 8
Rate of enrolment
average number of patients enrolled per site per month
Measured: Monthly starting at individual site initiation through to end of enrollment, estimated two years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2017
- Study start12 Mar 2018
- Primary completion31 Dec 2021
- Study completion31 Dec 2021
Why it stopped: infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants coming to an end.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 178 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), CancerCare Manitoba
- Responsible party
- Sponsor
- Investigators
- Ryan Zarychanski, MD MSc, Principal investigator, University of ManitobaAnand Kumar, MD, Principal investigator, University of ManitobaDean A Fergusson, PhD MHA, Principal investigator, University of Ottawa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03378466
- Sponsor's protocol ID
- HCA2017
- Acronym
- HALO
- Status last verified
- Jan 2021
- First submitted
- 9 Nov 2017
- Last updated
- 24 May 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT
- ClinicalTrials.gov ID
- NCT03378466
- Acronym / sponsor ID
- HALO / HCA2017
- Conditions
- Septic Shock, Vasodilatory Shock
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants coming to an end.
- Enrolment
- 178 participants (actual)
- Lead sponsor
- University of ManitobaUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR), CancerCare Manitoba
- Study start
- 12 Mar 2018 (actual)
- Primary completion
- 31 Dec 2021 (actual)
- Study completion
- 31 Dec 2021 (actual)
- First posted
- 19 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
Detailed description
Background and significance: Sepsis and septic shock account for 10% of admissions to the intensive care unit and constitute the second most frequent cause of death among admitted patients. The mortality rate associated with septic shock ranges from 30% to 50% and death is often due to multiple organ dysfunction coupled with systemic inflammation. Given the pathobiological relationship between coagulation and inflammation in sepsis, treatment with anticoagulants has been investigated in this population. Multiple lines of evidence suggest that heparin, a widely available, inexpensive anticoagulant, may improve clinical outcomes in sepsis, but high quality evidence to guide practice is lacking.
Hypothesis: Intravenous (IV) unfractionated heparin (UFH) reduces mortality and morbidity when administered to patients with suspected septic shock.
Study Design: A pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.
Setting: To increase the external validity/generalizability of the trial results, 20 sites in 4 countries will participate.
Study Population: Patients with systemic inflammation, vasopressor dependent shock, and signs of organ dysfunction.
Interventions: IV infusion of UFH at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to usual care to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x that of the reference aPTT value (approximately 59-99 seconds). Alternately, therapeutic anti-Xa values (ie. values typically targeted for the treatment of venous thromboembolism) can be targeted based on local practice. Duration of heparin infusion is for a maximum of 5 days (120 hours) or until death, ICU discharge or discontinuation of vasopressors. The dose of UFH has been informed by our observational study and meta-analysis that showed a benefit of UFH in patients receiving therapeutic doses.
Control group: Local standard care for venous thromboprophylaxis (i.e. not therapeutic) which may include SC LMWH, SC UFH, sequential compression devices or graduated compression stockings.
Outcomes: At the end of the HALO international phase II trial, an international DSMB will be presented with by-group efficacy (vasopressor-free days) data in the context of 90-day mortality, and safety (bleeding and transfusion). With these data the DSMB will suggest: a) terminating enrollment for futility (lack of efficacy) or harm, or b) continuing to the phase III trial along with a recommended sample size to detect a clinically relevant difference in 90-day mortality. Patients will be analyzed according to the treatment group to which they are allocated. By-group data will remain blinded to study investigators so that these patients may be included in the HALO international phase III RCT. Our analytic approach provides a rationale to either stop, or to justify further investment in a large international phase III trial.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Unfractionated Heparin (UFH) | Experimental | Drug: Unfractionated heparinUFH initiated at 18 IU/kg/hr |
| Venous thromboprophylaxis (VTE) | Other | Other: Venous thromboprophylaxis (VTE)as per local standard |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ≥ 18 years of age
- Refractory hypotension documented within 18 hours prior to enrolment that requires the institution and ongoing use of vasopressor agents, (phenylephrine, norepinephrine, vasopressin, epinephrine, midodrine or dopamine >5 mcg/kg/min) at the time of enrolment. Refractory hypotension is defined as a systolic blood pressure (SBP) less than 90 mm Hg, or a systolic blood pressure more than 30 mm Hg below baseline, or a mean arterial pressure (MAP) less than 65 mm Hg and receipt of ≥ 2 litres of intravenous fluid for the treatment of hypotension (≥ 1 litre if dialysis dependent end-stage renal disease or if the patient is felt to be in congestive heart failure).
- At least 1 other new organ dysfunction (in addition to refractory hypotension), defined by the following:
Key exclusion criteria (13 listed)
- Other forms of shock including cardiogenic, hemorrhagic, hypovolemic, neurogenic, or obstructive shock.
- Clinical suspicion or confirmation of a viral hemorrhagic shock syndrome including, but not limited to, dengue fever
- Rapid clinical improvement; vasopressors likely to be discontinued in the next 6 hours
- Received vasopressor therapy for greater than 18 hours prior to enrolment
- Bleeding Risk:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Unfractionated heparinAlso: HeparinUFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice. | Drug | Unfractionated Heparin (UFH) |
| Venous thromboprophylaxis (VTE)May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings | Other | Venous thromboprophylaxis (VTE) |
Primary outcome
Vasopressor-free days.
Time frame: 30 days
The goal of phase II trial is to provide the international Data Safety Monitoring Committee (DSMC) with a sensible estimate to justify continued enrollment in an adaptive (sample size) trial. Vasopressor use, reflecting cardiovascular collapse due to overwhelming systematic inflammation, is a key inclusion criterion for the trial and durable discontinuation of such drugs and meaningful clinical improvement. Vasopressor-free days has been recommended as a preferred clinical outcome in phase II trials in critical illness.
11 secondary outcomes
Clinical Outcome #1 - ICU mortality
Time frame: From date of randomization until the first documentation of death from any cause or ICU discharge date or 90 days, whichever came first
Clinical Outcome #2 - Hospital mortality
Time frame: From date of randomization to the first documentation of death from any cause or hospital discharge date or 90 days, whichever came first.
Clinical Outcome #3 - 90-day mortality
Time frame: Up to day 90
Clinical Outcome # 4 - ∆SOFA score (Sequential Organ Failure Assessment)
Time frame: Daily from randomization to ICU discharge or hospital discharge or time of death or to study day 9 if still in ICU or hospital.
Clinical Outcome # 5 - Hospital-free days to day 90
Time frame: from hospital admission to hospital discharge or time of death to day 90
Clinical Outcome #6 - Renal replacement therapy-free days to day 28
Time frame: from start of renal replacement therapy to study day 28
Safety Outcome #1 - Major Bleeding
Time frame: Assessed daily to day 8
Safety Outcome #2 - Minor Bleeding
Time frame: Assessed daily to day 8
Safety Outcome #3 - Suspected HIT (Heparin induced thrombocytopenia)
Time frame: Assessed daily to day 8
Safety Outcome #4 - Confirmed HIT (Heparin induced thrombocytopenia)
Time frame: Assessed daily to day 8
Rate of enrolment
Time frame: Monthly starting at individual site initiation through to end of enrollment, estimated two years
Results and safety
The study was stopped early (reason given: infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants coming to an end.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 May 2022.
Related trials for Septic Shock
RecruitingPhase 3
A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response
Septic Shock
RecruitingObservational study
Comparison of Cardiac Index Measurement Using Right Ventricular Pressure Curve Analysis and Thermodilution Via a Swan-Ganz IQ™ Catheter.
Septic Shock
Not yet recruitingObservational study
Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational Study
Sepsis
RecruitingPhase 3
Systematic Adjunction of Vasopressine in Septic Shock
Septic Shock
Not yet recruitingObservational study
Neutrophil Activation and NETosis in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ryan Zarychanski, MD MSc principal investigator
University of Manitoba
Anand Kumar, MD principal investigator
University of Manitoba
Dean A Fergusson, PhD MHA principal investigator
University of Ottawa
51 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Unfractionated heparin and Venous thromboprophylaxis (VTE) in people with Septic Shock and Vasodilatory Shock, run by University of Manitoba at 51 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 51 sites in Brazil, Canada, Pakistan, Philippines, Greece and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: infeasible to continue due-to inability to recruit during the COVID-19 pandemic and grants coming to an end.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vasopressor-free days. (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 May 2022.